# RCM Technologies, Inc.: Form 10-Q for the period ended Apr 2, 2022

- Company: [RCM Technologies, Inc.](/companies/rcmt.md) (CIK 700841)
- Form: 10-Q
- Filed: 2022-04-28
- Accepted by EDGAR: Apr 28, 2022, 16:11 ET
- Period: 2022-04-02
- Accession: 0001437749-22-010082
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/700841/000143774922010082/rcmt20220402_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/700841/000143774922010082/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-04-02.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-01-02 to 2022-04-02 | $82.0m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2022-01-02 to 2022-04-02 | $58.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-01-02 to 2022-04-02 | $23.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2022-01-02 to 2022-04-02 | $14.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-01-02 to 2022-04-02 | $9.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-01-02 to 2022-04-02 | $2.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-01-02 to 2022-04-02 | $6.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-01-02 to 2022-04-02 | $0.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-01-02 to 2022-04-02 | $0.64 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-01-02 to 2022-04-02 | 10,563,995 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2022-01-02 to 2022-04-02 | $2.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2022-01-02 to 2022-04-02 | $217.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2022-01-02 to 2022-04-02 | $2.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-04-02 | $859.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-04-02 | $63.1m | us-gaap:AssetsCurrent |
| Total assets | at 2022-04-02 | $84.2m | us-gaap:Assets |
| Current liabilities | at 2022-04-02 | $35.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-04-02 | $54.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-04-02 | $30.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 4,741 characters.

### COVID-19 Considerations

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to present various health, business and other challenges throughout the United States. As a result, we have temporarily closed or reduced many of our office locations, with a significant portion of our workforce working from home. The duration and ultimate magnitude of the disruption remains uncertain. We experienced a negative impact during fiscal 2020 and, for certain of our business lines, in fiscal 2021. The COVID-19 pandemic may negatively impact our business, results of operations, and financial position in fiscal 2022 and possibly beyond. The related financial impact, if any, cannot be reasonably estimated at this time.

The Company believes its Engineering and the Life Sciences and Information Technology segments have seen a decline in their field services work as their personnel have experienced constrained access to client facilities. It is difficult to determine the impact on revenue from the loss in field services work. The Company believes that an undetermined amount of field services work will eventually return as a portion of that work is mission-critical to our clients. While the Company has recently seen signs of improvement, given the uncertainties around COVID-19, the Company can give no assurances that it will see an increase in field services revenue. Additionally, the Company believes that COVID-19 has had a significant adverse impact on the budgets of many of its Aerospace and Utilities clients. The Company’s Aerospace clients have seen an impact to their commercial lines of business. A number of the Company’s Utility clients have been impacted by their customers’ inability to pay their monthly electric bills.

It is difficult to assess both the current and future impact from COVID-19 to the Specialty Health Care segment, due to the high degree of uncertainty around COVID-19 and the duration and extent of the pandemic, especially as it may impact schools where many of our personnel work. While the Specialty Health Care segment has a small number of billable professionals performing services from home, in particular, through its telehealth services offerings, most of its billable staff works at client locations. The majority of the Specialty Health Care segment’s services are historically delivered at schools and health care facilities. The Company believes that demand for much of its services is very high as a result of COVID-19. However, health care professionals, such as nurses and doctors, are scarce and difficult to recruit. Also, the Company believes that any major changes in the pandemic, such as a new variant, could adversely impact revenue. For example, if the Specialty Health Care segment’s school clients were to return to virtual learning as we experienced in 2020 and portions of 2021, the Specialty Health Care segment could experience a material decline in revenue. Conversely, the Specialty Health Care clients’ demand for the Company’s services may decline in the event the pandemic fully transitions to an endemic.

The Company’s priorities during the COVID-19 pandemic are protecting the health and safety of our employees and, especially in the healthcare segment, deploying our resources, including the talents of our employees, to help the communities we serve meet and overcome the current challenges. Our ability to continue to operate without any significant negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees, with particular measures in place for those working in our customer facilities.

While our revenue, gross profit and operating income were negatively impacted in fiscal 2020 on a consolidated basis and, for certain business lines, in fiscal 2021, we have maintained the consistency of our operations, to a substantial degree, from the onset of the COVID-19 pandemic. We intend to continue to adhere to our employee safety measures as we seek to ensure that any disruptions to our operations remain as limited as possible during the pandemic. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example, an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations. Any material changes to labor rates for the Company’s workforce may have a material negative impact to revenue, gross profit and operating income.

## Market risk

As filed, 1,178 characters.

The Company’s exposure to market risk for changes in interest rates relates primarily to the Company’s investment portfolio and debt instruments, which primarily consist of the Revolving Credit Facility. The Company does not have any derivative financial instruments in its portfolio. The Company places its investments in instruments that meet high credit quality standards. The Company is adverse to principal loss and ensures the safety and preservation of its invested funds by limiting default risk, market risk and reinvestment risk. As of April 2, 2022, the Company’s investments consisted of cash and money market funds. The Company does not use interest rate derivative instruments to manage its exposure to interest rate changes. Based on the Company’s variable-rate line of credit balances during the thirteen week period ended April 2, 2022, if the interest rate on the Company’s variable-rate line of credit (using an incremental borrowing rate) during the period had been 1.0% higher, the Company’s interest expense on an annualized basis would have increased by $0.2 million. The Company does not expect any material loss with respect to its investment portfolio.

## Controls and procedures

As filed, 2,443 characters.

The Company’s management, under the supervision and with the participation of the Company’s Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that those disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

A controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

As management prepares and executes its virtual financial close process, there could be related implications on the internal controls performed specifically in conjunction with the preparation, review, and filing of this report. There is a risk that moving to a virtual environment in response to COVID-19 could result in certain controls (e.g., financial closing and reporting controls) being overridden or performed less frequently, or that management could be designing and implementing new controls in response to new risks. In addition, in instances where relevant controls fail, and there are no compensating controls in place, there may be fewer opportunities to timely identify or remediate control deficiencies. There were otherwise no changes in the Company’s internal control over financial reporting during the thirteen week period ended April 2, 2022, that materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

### RCM TECHNOLOGIES, INC. AND SUBSIDIARIES PART II - OTHER INFORMATION

## Risk factors

As filed, 230 characters.

For information regarding factors that could affect the Company’s business, see the risk factors discussed under Part I, Item 1A, Risk Factors, of the Company’s Annual Report on Form 10-K for the fiscal year ended January 1, 2022.

Filed Apr 28, 2022.
Source: SEC EDGAR, the filing index for accession 0001437749-22-010082. Last ingested by Listed: Nov 13, 2026, 14:29 ET. No prices; not investment advice.
